MX2016013035A - Derivados de dihidrotiazina y dihidrooxazina que tienen actividad inhibidora de enzima de escision de proteina precursora amiloide 1 en sitio beta (bace1). - Google Patents
Derivados de dihidrotiazina y dihidrooxazina que tienen actividad inhibidora de enzima de escision de proteina precursora amiloide 1 en sitio beta (bace1).Info
- Publication number
- MX2016013035A MX2016013035A MX2016013035A MX2016013035A MX2016013035A MX 2016013035 A MX2016013035 A MX 2016013035A MX 2016013035 A MX2016013035 A MX 2016013035A MX 2016013035 A MX2016013035 A MX 2016013035A MX 2016013035 A MX2016013035 A MX 2016013035A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydrothiazine
- dihydrooxazine
- derivatives
- substituted
- inhibitory activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un compuesto que tiene un efecto de inhibir la producción de amiloide ß, especialmente un efecto de inhibir BACE1, y que es útil como un agente terapéutico o profiláctico para enfermedades inducidas por la producción, secreción y/o deposición de proteínas amiloides ß. Un compuesto de la fórmula (I) (ver Fórmula) en la que X es -S- o -O-, R3a es alquilo, haloalquilo, es alquilo, haloalquilo o similares, R2a es H, halógeno, alquiloxi, haloalquiloxi o similares, R2b es H o similares, R3b es H o alquilo, el anillo A y el anillo B es cada uno independientemente un carbociclo aromático sustituido o no sustituido, un heterociclo aromático sustituido o no sustituido o similares, y es alquilo sustituido o no sustituido o similares, o una sal farmacéuticamente sal aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014081524 | 2014-04-11 | ||
PCT/JP2015/062314 WO2015156421A1 (en) | 2014-04-11 | 2015-04-10 | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016013035A true MX2016013035A (es) | 2017-01-09 |
Family
ID=53284477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013035A MX2016013035A (es) | 2014-04-11 | 2015-04-10 | Derivados de dihidrotiazina y dihidrooxazina que tienen actividad inhibidora de enzima de escision de proteina precursora amiloide 1 en sitio beta (bace1). |
Country Status (15)
Country | Link |
---|---|
US (1) | US20170073337A1 (es) |
EP (1) | EP3129370A1 (es) |
JP (1) | JP2017510587A (es) |
KR (1) | KR20160141849A (es) |
CN (1) | CN106414431A (es) |
AR (1) | AR100049A1 (es) |
AU (1) | AU2015244702A1 (es) |
CA (1) | CA2945272A1 (es) |
EA (1) | EA201692048A1 (es) |
IL (1) | IL248228A0 (es) |
MX (1) | MX2016013035A (es) |
PH (1) | PH12016501891A1 (es) |
SG (1) | SG11201607999VA (es) |
TW (1) | TW201623295A (es) |
WO (1) | WO2015156421A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2012129168A (ru) † | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
CA2903215C (en) | 2013-03-08 | 2021-07-20 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
US20170066741A1 (en) | 2014-02-19 | 2017-03-09 | H. Lundbeck A/S | 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease |
US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
EP3271356B1 (en) | 2015-03-19 | 2019-10-16 | Eli Lilly and Company | Selective bace1 inhibitors |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
PE20181015A1 (es) | 2015-08-12 | 2018-06-26 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 |
WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
JP6616525B2 (ja) * | 2016-03-01 | 2019-12-04 | エフ.ホフマン−ラ ロシュ アーゲー | Bace1阻害剤 |
AU2019258575A1 (en) | 2018-04-27 | 2020-10-29 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
JP7127808B2 (ja) * | 2018-05-29 | 2022-08-30 | 国立大学法人山口大学 | フルオロアルキル基を含有するイミン類の製造方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
WO2006138217A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
EP1942105B8 (en) * | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
JPWO2010113848A1 (ja) | 2009-03-31 | 2012-10-11 | 塩野義製薬株式会社 | Bace1阻害作用を有するイソチオウレア誘導体またはイソウレア誘導体 |
JPWO2011058763A1 (ja) | 2009-11-13 | 2013-03-28 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
WO2011071109A1 (ja) | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
JPWO2011077726A1 (ja) | 2009-12-24 | 2013-05-02 | 塩野義製薬株式会社 | 4−アミノ−1,3−チアジンまたはオキサジン誘導体 |
CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
JPWO2012147762A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するbace1阻害剤 |
CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
KR20140041590A (ko) | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | [1,3]옥사진 |
WO2012168164A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
US8476264B2 (en) | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
CN104066727B (zh) | 2012-01-26 | 2019-04-26 | 霍夫曼-拉罗奇有限公司 | 氟甲基-5,6-二氢-4h-[1,3]噁嗪类 |
CN104470915B (zh) | 2012-06-26 | 2019-07-26 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的二氟-六氢-环戊二烯并噁嗪基类和二氟-六氢-苯并噁嗪基类 |
WO2014010748A1 (en) | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
JP2014101354A (ja) | 2012-10-24 | 2014-06-05 | Shionogi & Co Ltd | Bace1阻害作用を有するオキサジン誘導体 |
WO2014065434A1 (en) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
JP2014101353A (ja) | 2012-10-26 | 2014-06-05 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
WO2014098831A1 (en) | 2012-12-19 | 2014-06-26 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
EP2961749B1 (en) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
MA38556A1 (fr) | 2013-04-11 | 2017-09-29 | Hoffmann La Roche | Inhibiteurs de bace1 |
-
2015
- 2015-04-09 TW TW104111465A patent/TW201623295A/zh unknown
- 2015-04-10 JP JP2016558817A patent/JP2017510587A/ja active Pending
- 2015-04-10 CN CN201580031354.5A patent/CN106414431A/zh active Pending
- 2015-04-10 KR KR1020167031354A patent/KR20160141849A/ko unknown
- 2015-04-10 SG SG11201607999VA patent/SG11201607999VA/en unknown
- 2015-04-10 MX MX2016013035A patent/MX2016013035A/es unknown
- 2015-04-10 AR ARP150101090A patent/AR100049A1/es unknown
- 2015-04-10 WO PCT/JP2015/062314 patent/WO2015156421A1/en active Application Filing
- 2015-04-10 EP EP15727077.8A patent/EP3129370A1/en not_active Withdrawn
- 2015-04-10 US US15/302,892 patent/US20170073337A1/en not_active Abandoned
- 2015-04-10 CA CA2945272A patent/CA2945272A1/en not_active Abandoned
- 2015-04-10 EA EA201692048A patent/EA201692048A1/ru unknown
- 2015-04-10 AU AU2015244702A patent/AU2015244702A1/en not_active Abandoned
-
2016
- 2016-09-26 PH PH12016501891A patent/PH12016501891A1/en unknown
- 2016-10-06 IL IL248228A patent/IL248228A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160141849A (ko) | 2016-12-09 |
CA2945272A1 (en) | 2015-10-15 |
EP3129370A1 (en) | 2017-02-15 |
CN106414431A (zh) | 2017-02-15 |
JP2017510587A (ja) | 2017-04-13 |
PH12016501891A1 (en) | 2016-12-19 |
IL248228A0 (en) | 2016-11-30 |
EA201692048A1 (ru) | 2017-04-28 |
SG11201607999VA (en) | 2016-10-28 |
WO2015156421A1 (en) | 2015-10-15 |
TW201623295A (zh) | 2016-07-01 |
AR100049A1 (es) | 2016-09-07 |
AU2015244702A1 (en) | 2016-10-06 |
US20170073337A1 (en) | 2017-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501891A1 (en) | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity | |
MX2022011029A (es) | Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. | |
MX2017008417A (es) | Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1). | |
SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
MY153621A (en) | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity | |
PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
MX2023001876A (es) | Derivados de rapamicina. | |
MX2016017147A (es) | Compuestos de indazole substituidos como inhibidores de irak4. | |
TW201613872A (en) | IRAK4 inhibiting agents | |
MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
PH12017550004A1 (en) | Heterocyclic derivatives and use thereof | |
PH12017501160A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
MX2015015168A (es) | Derivados heterociclicos y sus usos. | |
PH12017502260A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
MX2015011180A (es) | Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc). | |
PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
PH12016501941B1 (en) | Use of heterocyclic compounds for controlling nematodes | |
PH12016501846A1 (en) | Tricyclic compound and jack inhibitor | |
PH12019501171A1 (en) | Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof | |
MX2019001228A (es) | Metodo de produccion del compuesto de pirazol-amida. | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
TN2013000074A1 (en) | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |